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Abstract
Hemorrhoidal disease (HD) is a frequent health problem 
with considerable repercussions on patients’ quality of life. 
However, much of the clinical practice related to HD is based 
on knowledge without scientific evidence and supported 
largely by empirical experience of the physician who deals 
with this pathology. As in other countries, the goal of this 
consensus is to establish statements supported by solid sci-
entific evidence and whose purpose will be to standardize 
and guide the diagnosis and management of HD both in the 
general population and in some particular groups of pa-
tients. © 2019 Sociedade Portuguesa de Gastrenterologia 
Published by S. Karger AG, Basel
Consenso da Sociedade Portuguesa de 
Gastrenterologia sobre o Diagnóstico e Tratamento 
da Doença Hemorroidária
Palavras Chave
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Resumo
A doença hemorroidária é uma patologia prevalente com 
repercussões consideráveis na qualidade de vida dos 
doentes. No entanto, muita da prática clínica relacionada 
com a doença hemorroidária é baseada em conhecimen-
tos sem evidência científica e apoiada largamente por 
uma experiência empírica por parte do médico que lida 
com esta patologia. À semelhança do que tem sido feito 
noutros países, o objetivo deste consenso foi estabelecer 
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statements suportados por evidência científica sólida e 
cuja finalidade será o de uniformizar e orientar o dia-
gnóstico e tratamento da doença hemorroidária quer na 
população em geral quer em grupos particulares de 
doentes. © 2019 Sociedade Portuguesa de Gastrenterologia  
Publicado por S. Karger AG, Basel
Introduction
Hemorrhoidal disease (HD) is a prevalent condition 
among industrialized societies. It is one of the leading 
causes for a visit to a coloproctology’s office. Given the 
large number of symptoms and associated patient dis-
tress, it is important that this disease is correctly diag-
nosed and treated.
Several guidelines and consensus have been published 
in recent years, addressing this issue [1, 2]. Nevertheless, 
a national guideline has not been published to date. 
Therefore, this workgroup was developed to elaborate 
statements that should aid in clinical practice.
Given that a lot of information regarding this field is 
either outdated or without published evidence, an effort 
was made to select a group of participants considered as 
experts in HD.
Prior to this meeting, an invitation was sent to 12 
prominent gastroenterologists with interest in proctology 
asking for the elaboration of statements addressing the 
different subthemes included in this document and, 
through research in scientific literature and/or clinical ex-
perience, the statements were revised and classified ac-
cording to the quality of evidence [3] (online suppl. Ap-
pendix 1; for all online suppl. material, see www.karger.
com/doi/10.1159/000502260). 
On the consensus meeting, each statement was voted 
(anonymously, through an electronic application) with 
the options A (Agree) and B (Disagree). A minimum of 10 
votes (80%) on the option A was necessary to obtain con-
sensus. If the statement did not reach 10 votes, it was ei-
ther changed until a consensus was obtained or excluded.
The meeting was held in Curia, Portugal, on  February 
24, 2019 with the scientific support of SPG – Sociedade 
Portuguesa de Gastrenterologia. 
A summary of the consensus is provided in online sup-
plementary Appendix 2 and an algorithm for the man-
agement of patients with suspected HD in Figure 1. 
Physiopathology of HD
The functional anal canal is approximately 4 cm in 
length (from the anal verge to distal rectum) [4–7]. The 
dentate line, approximately 2 cm above the anal verge, is 
a major anatomic point when considering the physiology 
and physiopathology of HD since, distal to the dentate 
line, the anal canal is lined with squamous epithelium 
covering the external hemorrhoidal plexus that is inner-
vated by the somatic nervous system and highly sensitive 
to pain [4–7]. Internal hemorrhoids are located proximal 
to the dentate line, where the anal canal is lined with co-
lumnar epithelium as in the rectum. This tissue lacks sen-
sitivity due to its innervation by the sympathetic and 
parasympathetic nervous systems, primarily distinguish-
ing only fullness and pressure [4–7]. There are typically 3 
major anal cushions above the dentate line (right anteri-
or, right posterior, and left lateral) often with some minor 
accessory cushions between them [8].
The pathogenesis of HD is most likely multifactorial 
including deterioration of anchoring connective tissue of 
anal cushions, downward displacement or prolapse of the 
hemorrhoidal tissue [9], hyperperfusion state and neo-
vascularization with abnormal distention of the arterio-
venous anastomoses and veins of the internal hemor-
rhoidal venous plexuses [10], overexpression of inflam-
matory mediators [11], and increased resting anal 
pressure [12, 13].
Chronic constipation is usually considered to contrib-
ute to the occurrence of HD by causing an increased 
shearing force on the anal cushions and decreased venous 
return leading to degeneration of the supportive tissue in 
the anal canal and distal displacement of anal cushions 
[14–16]. Although this concept has been recently chal-
lenged [17], it remains one of the most consistently ac-
cepted risk factor for HD. Other conditions associated 
with increased intra-abdominal pressure, such as preg-
nancy [18], prolonged sitting, or heavy lifting are believed 
to cause HD as a result of compromised venous drainage 
of hemorrhoid plexus [19]. Advancing age, obesity, and 
sedentarism have also been reported to contribute to 
symptoms onset [4, 20–23]. Chronic diarrhea is also a risk 
factor for developing HD due to frequent stool passage 
causing local trauma and weakening of the anal canal lin-
ing [13, 24]. Data are inconsistent regarding the pre-
sumed correlation between HD and habits such as smok-
ing, spicy foods, or alcohol consumption [7, 25]. There is 
currently no consistent scientific evidence regarding any 
genetic predisposition to HD [26].
Epidemiology
HD is commonly diagnosed in clinical practice [26]. 
The reported prevalence in adults is highly variable, from 
4.4% in self-reporting surveys [27] to 38.9% in screening 
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colonoscopy setting [23]. HD affects both sexes equally, 
with a peak prevalence occurring between the ages of 45–
65 years, being unusual before the third decade [27].
Clinical Evaluation and Diagnostic Tests
Statement 1
A detailed history and proctological examination are 




Anoscopy is the gold standard for the evaluation of the 
anus if HD is suspected (moderate-quality evidence).
Agreement: 100%.
Statement 3
Flexible sigmoidoscopy should be performed in pa-
tients with rectal bleeding. Colonoscopy is indicated in 
patients over the age of 50 years (earlier if there is family 
history of colorectal cancer [CRC] or another condition 




Internal HD is associated with painless bleeding (usu-
ally related to bowel movement), mucus discharge, soil-
ing, and pruritus [5].
When patients complain of a significant anal pain, 
other diagnosis must be considered, such as anal fissure 
or inflammatory bowel disease (IBD) [5, 27].
Clinical suspicion of HD
● Detailed anamnesis and proctological examination with anoscopy
● Flexible sigmoidoscopy/colonoscopya
Internal HD confirmed Other diagnosis
Manage accordinglyGoligher classificationb
Treatment of HD in special groups of patients
Hemorrhoidal disease complications
Conservative or surgical treatmenthExternal hemorrhoidal thrombosis
Conservative treatment (topical agents, anal hygiene). Consider surgical
excision if the symptoms are refractory to medical treatment or if the
patient feels discomfort due to aesthetical reasons
Perianal skin tags
Patients taking antiplatelet and/or anticoagulant medication Consider sclerotherapy or IRC
Conservative measures + sclerotherapyfPatients with impaired immunity





in selected cases) Surgery
e
Grade II Grade III Grade IV
● Dietary modification with adequate fluid and fiber intake and measures that
maintain proper bowel habitsc
● Consider the use of venotropic drugs and topical treatment as adjuvant therapy
Fig. 1. Algorithm for the management of patients with suspected 
hemorrhoidal disease. a Colonoscopy is indicated in patients over 
the age of 50 years (earlier if there is family history of CRC or an-
other condition predisposing to CRC) or if any alarm symptom is 
present; b consider using a symptom-based score, such as Soder-
gren score, to evaluate the severity of the HD; c advise avoiding 
excessive straining and limit the time at defecation; d medical man-
agement is enough for most patients. Some cases may require of-
fice-based treatment. RBL may be difficult to perform in such 
small vascular cushions; e the adopted type of surgical technique 
will depend on local expertise and should be a joint decision be-
tween the doctor and the patient; f studies have suggested a poten-
tial benefit of antibiotic prophylaxis in these patients owing to the 
risk of bacteremia after sclerotherapy; g there are no trials evaluat-
ing office-based therapies in pregnant women; therefore, they 
should probably be avoided during this period; h  surgical treat-
ment is effective in the prevention of recurrence and symptom 
control when applied during the first 48–72 h after symptoms on-
set. HD, hemorrhoidal disease; RBL, rubber band ligation; IRC, 
infrared coagulation.
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Patient history must include information regarding the 
presence of alarm symptoms, whether constipation or diar-
rhea coexist and relationship between symptoms and def-
ecation. Family history must also be included with a de-
tailed cancer history to stratify CRC risk and history of IBD.
A proctological examination should be performed al-
lowing the evaluation of the anal verge and its structures 
excluding a distal rectal mass or an anorectal abscess [8, 
28]. Moreover, anoscopy seems to be the most accurate 
method to diagnose HD and can be performed in the of-
fice setting with no prior preparation [28, 29].
Patients over the age of 50 years or with alarm symp-
toms/signs (anemia, iron deficiency, abdominal pain, di-
arrhea, weight loss, or fever) or with risk factors for CRC/
IBD should undergo colonoscopy. It also should be high-
lighted that HD alone does not affect the prevalence of 
positive occult blood tests so, in case of a positive result, 
it should not be attributed to HD until a colonoscopy is 
performed [30–32].
Flexible sigmoidoscopy should be considered in pa-
tients who do not meet any of the criteria described above.
HD Grading
Statement 4
Although never validated, the most widely used score 
is the Goligher classification. Other classification systems 




A symptom-based score, such as Sodergren score, can 




No unified tool exists to classify the severity of HD [2, 
33]. The most widely used is the Goligher classification 
[34]. It categorizes only internal hemorrhoids and defines 
4 grades of HD according to the most prolapsed pile. 
However, there is a frequent disparity between worsening 
symptoms and Goligher grade increment.
New classification systems for HD were proposed over 
the past 3 decades [35–38]. Some authors categorized HD 
in bleeding, prolapsing, thrombotic, and mixed HD [37]. 
This classification, based on histological evaluation of the 
anal canal in different stages of life, shed new light on the 
pathophysiology of HD. Other authors, using a retro-
flexed colonoscope, proposed a classification based on a 
detailed anatomical description [38]. Their algorithm in-
cluded the degree of mucosal elevation of the rectal col-
umns, changes in color, and the existence and size of hy-
pertrophied anal papillae evaluated by colonoscopy. The 
Sodergren score [39] was developed and validated in 2015 
using a simple symptom-based scoring system to quan-
tify the severity of HD. In this study, 50 patients were 
scored with rectal bleeding according to the severity and 
frequency of pruritus, pain at rest, pain at defecation, and 
prolapse.
The single pile hemorrhoid classification (2015) is a 
new tool that considers the number of pathological piles, 
the characteristics of each internal pile (incorporating 
here the Goligher classification), and the characteristics 
of each external pile [33].
Although interesting from a descriptive point of view, 
these new classification systems are not widely used, per-
haps because of their complexity. Probably no scoring 
system will ever be completely satisfactory.
Medical Management of HD
Diet, Transit Modifiers, and Laxatives
Statement 6
Dietary fiber (in food or as supplement) decrease 
bleeding and the recurrence of symptoms. The use of fi-
ber is recommended in the treatment of acute episodes 
and to prevent recurrence (high-quality evidence).
Agreement: 92%.
Statement 7
Patients with HD benefit from measures that maintain 
proper bowel habits such as avoiding straining and limit-
ing the time at defecation (moderate-quality evidence).
Agreement: 100%.
Rationale
As discussed above, HD has been considered to be 
caused by a low-fiber diet and constipation [40, 41]. Med-
ical therapy involves dietary modification with adequate 
fluid and fiber intake, along with avoiding straining as 
well as diarrhea [42]. Data on fiber have been assessed in 
a systematic review and meta-analysis of 7 trials, which 
included 378 patients randomized in 2 groups: fiber 
group versus nonfiber group [43]. The results suggested 
that fiber has an apparent beneficial effect. Alongside 
with dietary supplementation, patients benefit from mea-
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sures that maintain proper bowel habits such as avoiding 
straining during passing motions, limiting the time at 
defecation, and once a day defecation [44]. There is lack 
of supporting evidence for the efficacy of other laxatives 
in the treatment of HD.
Venotropic Drugs and Topical Treatment
Statement 8
Venotropic drugs seem to be effective in the treatment 
of symptomatic HD. There is a lack of evidence about op-
timal dosage, duration of treatment, or superiority of a 
specific drug (moderate-quality evidence).
Agreement: 100%.
Statement 9
Topical treatment may be useful in the short-term 
treatment of symptoms of HD but, so far, its use is not 




The main goal of pharmacological treatment is to re-
lieve acute symptoms of HD rather than reverting its 
chronic structural changes. Venotropics are a heteroge-
neous class of drugs used to treat chronic venous insuffi-
ciency [45] that have also been proposed for the treatment 
of HD [46]. Most of these drugs are derived from natural 
products extracted from plants, predominantly bioflavo-
noids. The precise mechanism of action has not been well 
established. There is some evidence in the literature that 
this class of drugs plays a role in the control of symptoms 
from HD [46]. A meta-analysis of 14 randomized con-
trolled trials involving 1,514 patients and comparing var-
ious flavonoids formulations (diosmin + hesperidin mi-
cronized purified flavonoid fraction, diosmin, and ruto-
sides) with placebo or no therapy reported an overall 
significant symptomatic improvement, namely, a benefi-
cial effect on bleeding, pain, and itching. Moreover, the 
few studies evaluating symptom recurrence also showed a 
favorable effect [47]. A more recent Cochrane review ex-
panded this evaluation to 24 trials involving 2,334 patients 
comparing venotropics (mostly flavonoids with some 
studies also evaluating calcium dobesilate) with a control 
intervention or no treatment and found relatively similar 
favorable results in overall improvement and in each 
symptomatic parameter [48]. No serious adverse events 
were reported with bioflavonoids besides mild gastroin-
testinal disturbances [47, 48]; however, agranulocytosis 
has been described with calcium dobesilate [49].
Despite these encouraging results, both the Cochrane 
review and the meta-analysis emphasize the limitations 
in methodological quality and the heterogeneity of data 
among trials, leaving uncertainty about the real efficacy 
of venotropics in the treatment of symptomatic HD and 
advising that larger and better designed trials are neces-
sary to achieve high-quality evidence.
Drugs available for topical application (mostly oint-
ments or creams and suppositories) may contain analge-
sics/anesthetics (e.g., cinchocaine), steroids (e.g., hydro-
cortisone), venotropics (e.g., ruscogenin), spasmolytics 
(e.g., trimebutin), vasoconstrictors (e.g., phenylephrine), 
antiseptics, and emollients, either isolated or in associa-
tion. The mechanism of action of some of these drugs has 
not been clarified. Evidence of efficacy has not been ad-
equately demonstrated as most studies involve few pa-
tients and centers, have not been adequately designed or 
are outdated, and have not been replicated. Even though 
some studies involved significant number of patients, 
such as the review on policresulen plus cinchocaine re-
porting beneficial effect in 1,904 (83.2%) out of 2,287 pa-
tients [50] or the review on several studies of tribenoside 
plus lidocaine [51], strong evidence cannot be drawn 
from the studies designed to provide a clear recommen-
dation. Caution must be taken with prolonged or iterative 
use of topical medication because allergic reactions or 
sensitization may occur [52–54]. 
A few more recent and so far isolated reports of ran-
domized clinical trials showed benefit from a gel contain-
ing hyaluronic acid with tea tree oil and methyl-sulfonyl-
methane in a single-center study with a small number of 
patients [55] and from an intra-anal ointment with ifer-
anserin, a selective serotonin receptor antagonist, evalu-
ated in a multicentric study [56].
A Cochrane review on traditional Chinese medicine 
herbs found no evidence to support its use in HD [57].
Office-Based Treatment of HD 
Rubber Band Ligation
Statement 10
Rubber band ligation (RBL) is recommended as first-
line treatment for internal grade II HD and for selected 
patients with grade III that do not respond to medical 
treatment. This technique is more effective and equally 
safe compared to sclerotherapy (liquid sclerosants) and 
infrared coagulation (IRC; high-quality evidence).
Agreement: 92%.
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Statement 11
For internal grade II HD, RBL has similar efficacy but 




Interventional management of HD can be divided in 
office-based or surgical procedures [58, 59].
The various nonsurgical treatments can be performed 
as outpatient procedures without anesthesia [59].
RBL involves placing rubber bands around hemor-
rhoids until they eventually fall off. It is a quick, simple, 
inexpensive procedure [59]. The elastic bands are ap-
plied on an insensitive area just above the dentate line to 
strangulate the piles leaving an area where inflammation 
fixes the mucosa to the submucosa preventing subse-
quent development of new hemorrhoidal tissue and is 
the most widely used nonsurgical treatment for patients 
with grade II or III HD [60]. Data regarding efficacy of 
RBL in grades I and IV are occasionally reported. The 
overall subjective improvement with RBL ranges from 73 
to 84% [60]. A meta-analysis of 18 randomized trials 
comparing various treatment methods for grades I to III 
HD concluded that RBL was more effective than sclero-
therapy and that patients who underwent ligation were 
less likely to need subsequent therapy [61]. Also, com-
pared to excision hemorrhoidectomy, RBL has similar 
results but without the side effects of excision hemor-
rhoidectomy for the treatment of grade II HD [59]. Al-
though RBL is more painful than other outpatient mo-
dalities, complication rates are similar [61]. Postopera-
tive pain ranges from 8 to 80% in different randomized 
controlled trials (RCT) [60]. Postoperative bleeding 
ranges from 1.20 to 36% in the majority of RCT, but there 
is one trial that reported 50% [60, 62–64]. Other compli-
cations include vagal symptoms, chronic ulcers, pria-
pism, difficulty in urination, hemorrhoidal thrombosis, 
and, although extremely uncommon, severe pelvic sepsis 
[58]. Recurrences of bleeding and prolapse at follow-up 
occur, respectively, in 10–18% and in 2.2% of patients; 1 




Sclerotherapy with liquid sclerosants is safe but poorly 
effective and therefore should be used only for grade I in-
ternal HD (high-quality evidence). Since postprocedural 
bleeding is uncommon, it should be considered for pa-




The use of other sclerosing techniques, such as polido-
canol foam and aluminum sulfate and tanic acid (ALTA), 
seems to be safe and effective even in patients under an-
ticoagulation and/or antiplatelet therapy. The efficacy 
and safety compared to other office-based procedures are 
yet to be defined (low-quality evidence).
Agreement: 100%.
Rationale
Internal HD can be fulgurated or sclerosed through 
injection [65]. As with RBL, sclerotherapy does not re-
quire anesthesia (local or intravenous). The procedure is 
performed through an anoscope, being the sclerosant in-
jected into the hemorrhoidal cushions above the dentate 
line [7, 60].
Sclerotherapy (with liquid sclerosants) is considered 
safe but poorly effective and, therefore, used only for 
small hemorrhoids. Postprocedural bleeding is uncom-
mon and so should be considered for patients who have 
an elevated bleeding risk, such as those receiving antico-
agulants.
The interpretation of published studies comparing 
sclerotherapy with elastic banding and hemorrhoidecto-
my is not always easy. Sclerosants used vary, as does the 
dose, injection method, puncture site, and the type of nee-
dle used. On the other hand, subjective evaluation of pro-
lapse reduction, intermittent blood loss, and recurrence 
of HD make the analysis difficult.
Among the various sclerosing agents described, 2 
have stood out in recent years for their effectiveness and 
safety: ALTA and polidocanol foam. An RCT with ALTA 
reported resolution of bleeding in 69–88% of grade I HD 
[66], while 3 case series showed an improvement of 
bleeding in 100% of grades II and III HD [65, 67, 68]. 
More than 90% of prolapses resolution in grade II HD is 
reported in an RCT and 2 case series [66, 68, 69]. Good 
results are shown also for grade III, but data are reported 
only by case series. A prospective study showed an over-
all prolapse improvement in 100% of patients [70], while 
Yano reported 52% of improvement of prolapse in III 
degree [71]. Miyamoto et al. [69] and Tokunaga [72] in 
their case series showed an improvement for grade IV, 
too.
In Portugal, liquid polidocanol 1 or 2% is commonly 
injected through the anoscope in low doses. However, 
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polidocanol foam seems to be a better sclerosant than the 
liquid form [73, 74].
In a recently published Portuguese study, 2,000 pa-
tients were treated with polidocanol foam (without con-
trol group). The authors concluded that this therapy 
was very successful, with 98% of the patients reporting 
satisfaction regarding bleeding control and prolapse re-
duction. Complications were rare and usually minor 
[75].
Complications of sclerotherapy are uncommon, with 
the most frequent being minor discomfort, tenesmus, or 
bleeding with the injection. The major complications are 
most often iatrogenic, owing to misplaced injections into 
nonhemorrhoidal tissues or with systemic injections into 
the vasculature. Urinary retention, rectourethral fistulas, 
rectovaginal fistulas, rectal perforations, infections, nec-
rotizing fasciitis, sepsis, and death are rare complications 
[76–78].
Other Techniques: IRC, Cryotherapy, 
Eletrocoagulation, and Heater Probe
Statement 14
IRC is an effective procedure in the treatment of grades 
I and II HD. When compared to RBL, IRC shows less 




Other office-based procedures have shown inconsis-
tent results, namely, electrotherapy (moderate-quality ev-
idence), cryotherapy, heater probe, and argon plasma co-
agulation (high-quality evidence). Their use is not sup-
ported by recent evidence.
Agreement: 92%.
Rationale
In addition to the techniques described earlier, a va-
riety of procedures can be used for HD: IRC, bipolar 
diathermy (BD), direct current electrotherapy (DCE), 
cryotherapy, and heater probe. For these therapeutic 
techniques, there are not enough controlled studies, par-
ticularly recent, and many authors consider that they 
should be regarded as obsolete [79].
IRC focuses infrared radiation from a tungsten-halo-
gen lamp via a polymer probe tip, resulting in protein 
necrosis within the hemorrhoid. One RCT evaluated the 
efficacy of IRC, flavonoids, and combination therapy for 
5 days: the percentages of improvement of IRC for differ-
ent grades of HD were 78, 51, and 22% for grades I, II, and 
III HD, respectively, and efficacy increased when the 
technique was associated with flavonoids; interestingly, 
the efficacy of IRC alone was similar to 5 days of flavo-
noids alone [80]. RCTs comparing IRC with RBL [81–84] 
showed that both were well-accepted and highly effica-
cious methods for the treatment of internal hemorrhoids; 
in general, RBL was more effective in controlling symp-
toms and needs fewer additional treatments but is associ-
ated with more pain than IRC.
BD is a studied treatment for grades I, II, and III HD. 
Success rates range from 88 to 100% in randomized trials 
but do not eliminate prolapsing tissue [31]. About 12% of 
patients experience pain, bleeding, fissure, or spasm of 
the internal sphincter [31]. Compared with IRC, BD has 
some practical advantages but results are similar [85]. 
Comparing BD with heater probe efficacy was the same, 
but pain was more common and the time to symptom 
relief was shorter with heater probe [86].
DCE has no advantage compared with standard med-
ical therapy in an RCT [87] and a limited control of pro-
lapse in higher grade HD [88]. In another RTC, although 
more painful than sclerotherapy, DCE is a safe and a 
highly satisfactory procedure for treating early HD [89]. 
However, DCE has not been widely accepted because of 
the lengthy treatment time and similar efficacy compared 
with BD [90–92], RBL [87], and sclerotherapy [88]. 
As for cryotherapy, the cryoprobe of liquid nitrogen is 
applied to the hemorrhoid for about 3 min to produce 
liquefaction of frozen tissue, over the ensuing 2–3 weeks. 
Despite initial enthusiasm, this procedure is now only 
rarely used because of prolonged pain, foul-smelling dis-
charge, and a greater need for additional therapy than 
closed hemorrhoidectomy [31].
Treatment of HD in Special Groups of Patients
Statement 16
In patients taking antiplatelet and/or anticoagulant 
medication, the risk of bleeding is increased after RBL 
(low-quality evidence). In these patients, sclerotherapy 
appears to be safe (moderate-quality evidence).
Agreement: 100%.
Statement 17
Instrumental interventions should be used with cau-
tion in patients with impaired immunity. Antibiotic pro-
phylaxis might be beneficial after office-based procedures 
(low-quality evidence).
Agreement: 100%.
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Statement 18
The first-line treatment of symptomatic HD during 
pregnancy should include a fluid and fiber-rich diet 




In pregnant women, rutosides (high-quality evidence), 
combination of tribenoside and lidocaine (moderate-
quality evidence), and hydrocortisone creams (low-quali-
ty evidence) seem effective in reducing symptoms of HD. 
Although preliminary data suggest no increased risk dur-
ing pregnancy, these therapies should be avoided during 
the first trimester (low-quality evidence).
Agreement: 92%.
Rationale
Antiplatelet and anticoagulant medication appear to 
increase the risk of bleeding after RBL with published re-
ports of massive and life-threatening hemorrhage [93–
96]. In a large retrospective study of 805 patients under-
going RBL, higher bleeding rates were encountered in pa-
tients on warfarin (25%) and acetylsalicylic acid (7.5%) 
compared with patients not taking these medications 
(2.9%) [64]. It is believed that the highest risk of bleeding 
occurs between 10 and 14 days after the procedure [62, 
93, 94]. This has led many authors to recommend patients 
to stop their medication 7–10 days before banding, fol-
lowed by a further 7–10 days thereafter [93, 97]. In a large 
retrospective observational study including 364 patients 
undergoing RBL, withholding antiplatelet medication 
7–10 days after the procedure appeared to equalize the 
risk of bleeding to that of patients not taking antithrom-
botic medications [97].
In a case-matched series of 37 patients receiving sclero-
therapy for symptomatic HD while on antiplatelet and/or 
anticoagulant therapy, there was no difference in post-
procedure bleeding rates [65].
In a prospective study, 120 patients with liver cirrhosis 
without coagulation disorders were randomized to receive 
RBL or sclerotherapy for the treatment of HD. Both thera-
pies proved to be safe and effective [98]. In another pro-
spective randomized trial of 26 patients with cirrhosis and 
HD, resolution of symptoms and complications were sim-
ilar between patients receiving RBL and stapled hemor-
rhoidopexy [99]. Even though studies seem to suggest that 
office-based therapy is beneficial in patients with liver cir-
rhosis, the authors have considered that there is not enough 
solid evidence to elaborate a statement on this matter.
HD is present in up to 10% of patients infected with 
human immunodeficiency virus [100]. Older studies 
have reported impaired tissue healing and an increased 
risk of anorectal sepsis in immunocompromised patients 
[101]. Wound healing may be specially compromised in 
patients with low CD4 counts [102]. This had led to the 
general belief that interventions should be avoided or per-
formed with careful consideration in immunocompro-
mised patients. Other reports, however, have demon-
strated that surgery for HD is safe in these patients [103]. 
At this moment, it seems wiser to use conservative mea-
sures (fluid and fiber-rich diet, laxatives, warm sitz baths) 
as the first-line treatment [104]. There is a paucity of data 
evaluating the safety and efficacy of instrumental tech-
niques in immunocompromised patients with HD. Anec-
dotal reports have shown significant complications in hu-
man immunodeficiency virus patients following RBL 
[105]. However, sclerotherapy may be an attractive alter-
native in these patients [70]. Studies have suggested a po-
tential benefit of antibiotic prophylaxis in these patients 
owing to the risk of bacteremia after sclerotherapy [106]. 
The prevalence of HD during pregnancy can reach 
85% during the third trimester [107, 108]. Treating con-
stipation by increasing fluid and fiber intake and taking a 
warm sitz bath 3 times a day may be helpful in improving 
symptoms from HD. In a prospective comparative study, 
relief of HD symptoms was achieved in all 284 patients in 
the warm sitz bath group but only in 179/211 patients in 
the control group [109].
Two randomized controlled trials including over 150 
pregnant women have shown that rutosides are effective 
in treating symptomatic HD [110, 111]. The safety of ru-
tosides was demonstrated in another randomized con-
trolled trial including 69 pregnant women with venous 
insufficiency [112]. The combination of tribenoside and 
lidocaine suppositories has been studied in an old ran-
domized parallel double-blind randomized trial versus li-
docaine suppositories (n = 21 vs. 20) and hydrocortisone 
suppositories (n = 13 vs. 13) [113]. In both occasions, the 
combination of tribenoside and lidocaine appeared to be 
safe and to relieve HD symptoms. In an observational 
study, 82.5% of 33 pregnant women reported clinical im-
provement with oral tribenoside or a combination of 
tribenoside and lidocaine suppositories [114]. Again, no 
adverse events were reported. Finally, in a population-
based study, oral tribenoside was associated with a higher 
risk of congenital hydrocephalus in children. However, 
this finding was based on only 4 cases [115]. Topical hy-
drocortisone has shown modest effectiveness in control-
ling hemorrhoidal symptoms in a randomized controlled 
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study against a modified toilet seat device [116]. No side 
effects were reported in the study. In a prospective obser-
vational study, topical hydrocortisone cream was effec-
tive in decreasing HD symptoms in 88 pregnant women 
[117]. Side effects were not reported in both studies. The 
safety of topical hydrocortisone has been evaluated in a 
prospective nonrandomized multicenter study compar-
ing 204 treated pregnant women with 204 controls. No 
differences were found in birth weight or rates of prema-
turity [118]. In an open study of 50 pregnant women, a 
combination of diosmin and hesperidin proved effective 
in treating HD. Although lack of a control group pre-
cludes conclusions, significant adverse events were not 
noted [119].
We could not find any studies addressing the safety of 
any of the former drugs in lactating women.
There are no trials evaluating office instrumental ther-
apies in pregnant or lactating women. As concerns re-
garding their safety during pregnancy or lactation exist, 
they should probably be avoided during this period.
Lastly, we should mention a specific group of patients, 
those with Crohn’s disease. HD has been estimated in a 
2012 study as affecting 1.6% of patients with Crohn’s dis-
ease [120], but higher rates of prevalence (7%) have been 
reported [121]. Surgery is usually not indicated in these 
patients, especially if the disease is not quiescent [122]. 
Conservative management is usually advised but none-
theless is often not effective in resolving HD. There is a 
paucity of studies involving the office-based treatment of 
HD in Crohn’s disease [121], and as such, the authors 
have decided not to elaborate a statement on the matter.
HD Complications
Statement 20
The treatment of irreducible hemorrhoidal prolapse 
should be surgical (high-quality evidence). New sclerosing 




Treatment of external hemorrhoidal thrombosis can 
be conservative or surgical (high-quality evidence).
Agreement: 92%.
Rationale
The treatment of irreducible hemorrhoidal prolapse 
(Goligher grade IV) is surgical [123]. Although excision-
al hemorrhoidectomy is the most widely used technique 
in the world for irreducible hemorrhoidal prolapse, the 
comparison between surgical techniques for the treat-
ment of grade IV HD does not show superiority of one 
method over another and is mainly a joint decision be-
tween the doctor and the patient [123, 124].
Although surgical treatment is quite effective in the 
treatment of external hemorrhoidal thrombosis, allowing 
the prevention of recurrence and symptom control, there 
is a clear lack of randomized prospective studies that al-
low to establish surgery as the gold standard in the treat-
ment of this condition [125–127]. Surgical excision of ex-
ternal hemorrhoidal thrombosis relieves symptoms 
markedly on the fourth postoperative day when com-
pared to conservative treatment [125]. One of the main 
doubts that remain is the optimal timing for surgery. 
Also, there is no evidence in the literature to support con-
servative treatment in the first 48–72 h of symptoms; 
however, clinical practice seems to favor this approach 
[126]. Thus, choosing between conservative treatment 
and surgery should take into account the patient’s will 
and the clinician’s experience [127].
There is a lack of studies aimed at the treatment of anal 
skin tags in patients with no other rectal pathology. Refer-
ence should be made to the existence of guidelines (which 
take the form of a systematic review) of the German So-
ciety of Coloproctology in conjunction with the German 
Society of Dermatology, but these guidelines are mostly 
based on studies over 30 years old [128]. In these guide-
lines, anal skin tags are considered to be mainly an es-
thetic problem, which only becomes more burdensome 
when it interferes with the hygiene of the patient. Thus, 
asymptomatic anal skin tags should not be treated, and 
careful hygiene should be carried out with water. The 
treatment of symptomatic anal skin tags should be made 
conservatively, with topical agents, anal hygiene, and reg-
ular habits of defecation. Fibrous skin tags that cause skin 
irritation or pressure on contralateral areas can be re-
moved surgically.
Final Thoughts
HD is a common disorder that appears very often on 
the clinical setting. Nevertheless, from our experience, 
most of the knowledge and techniques that gastroenter-
ologists use in the management of this disease are based 
in somewhat outdated literature or from peer learning, 
and no comprehensive approach to this matter is avail-
able for the Portuguese reality.
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Our goal was to elaborate statements based on the 
most recent literature paying attention to evidence level. 
This way, we aimed to reinforce correct patterns of knowl-
edge and practice to meet the standards of published evi-
dence also trying to highlight new information on the 
subject. Another end point we would like to achieve is the 
uniformization of clinical practice regarding this disease 
among gastroenterologists.
It should be noted, however, that some of the topics 
need further research and emphasis should be made on 
more studies regarding several of the office-based meth-
ods available, such as sclerotherapy.
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